These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20824449)

  • 1. Rare diseases social epidemiology: analysis of inequalities.
    Kole A; Faurisson F
    Adv Exp Med Biol; 2010; 686():223-50. PubMed ID: 20824449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.
    Stakisaitis D; Spokiene I; Juskevicius J; Valuckas KP; Baiardi P
    Medicina (Kaunas); 2007; 43(6):441-6. PubMed ID: 17637514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rare diseases, definitions and epidemiology].
    Donnart A; Viollet V; Roinet-Tournay M
    Soins Pediatr Pueric; 2013; (274):14-6. PubMed ID: 24228328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legal assessment of current situation on orphan patients in Lithuania.
    Spokiene I
    Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regulatory overview about rare diseases.
    Llinares J
    Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rare diseases and their patient organization: the Hungarian Federation of People with Rare and Congenital Diseases].
    Pogány G
    Orv Hetil; 2014 Mar; 155(9):329-33. PubMed ID: 24566696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays.
    Zurynski Y; Deverell M; Dalkeith T; Johnson S; Christodoulou J; Leonard H; Elliott EJ;
    Orphanet J Rare Dis; 2017 Apr; 12(1):68. PubMed ID: 28399928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why we should care about ultra-rare disease.
    Harari S
    Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a European Union framework for actions in the field of rare diseases.
    Moliner AM
    Adv Exp Med Biol; 2010; 686():457-73. PubMed ID: 20824460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and regulatory aspects of orphan drugs.
    Shani S; Yahalom Z
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 20. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.